NVP-BBD130
NVP-BBD130 is a potent, stable, ATP-competitive and orally active dual PI3K and mTOR inhibitor[1]. NVP-BBD130 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
853910-61-9
UNSPSC
12352005
Target
MTOR; PI3K
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nvp-bbd130.html
Solubility
10 mM in DMSO
Smiles
N#CC(C)(C)C1=CC=C(N2C(N(C)C3=CN=C4C=CC(C#CC5=CC=CN=C5)=CC4=C32)=O)C=C1
Molecular Formula
C28H21N5O
Molecular Weight
443.50
References & Citations
[1]Marone R, et al. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res. 2009 Apr;7 (4) :601-13.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15313382 1 Vial
Lentiviral human RAD54L shRNA (UAS) - Lentiviral human RAD54L shRNA (UAS, RFP) (25)
Sign In for Pricing
View Details K6675702 1.0 µg DNA
l7Rn6 sgRNA CRISPR Lentivector (Rat) (Target 1)
Sign In for Pricing
View Details 
MBS6385291-01 0.1 mL
Menin (MEN1, Multiple Endocrine Neoplasia I, MEAI, SCG2, Wermer Syndrome, Zollinger Ellison Syndrome, ZES) (AP)
Sign In for Pricing
View Details MBS6385291-02 5x 0.1 mL
Menin (MEN1, Multiple Endocrine Neoplasia I, MEAI, SCG2, Wermer Syndrome, Zollinger Ellison Syndrome, ZES) (AP)
Sign In for Pricing
View Details 